Successful Introduction of Benralizumab for Eosinophilic Ascites.
benralizumab
eosinophilic ascites
eosinophilic gastroenteritis
steroids
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
06 Jan 2024
06 Jan 2024
Historique:
received:
30
11
2023
revised:
15
12
2023
accepted:
22
12
2023
medline:
23
1
2024
pubmed:
23
1
2024
entrez:
23
1
2024
Statut:
epublish
Résumé
Eosinophilic ascites is a rare disorder, reported in both adult and pediatric patients, characterized by high eosinophil counts in the peritoneal fluid. Eosinophilic ascites appears as a manifestation of various diseases such as parasitic and fungal infections, malignancy, and hypereosinophilic syndrome. It also represents an uncommon manifestation of eosinophilic gastroenteritis, usually treated with corticosteroids. We present the case of a 16-year-old woman with abdominal distention related to abundant ascites. Further work-up concluded that it was eosinophilic gastroenteritis complicated with eosinophilic ascites. The patient was on oral steroids for three weeks, but various abdominal relapses were observed, leading to the introduction of benralizumab, as a steroid-sparing therapy with a favorable outcome.
Identifiants
pubmed: 38255222
pii: biomedicines12010117
doi: 10.3390/biomedicines12010117
pii:
doi:
Types de publication
Case Reports
Langues
eng